Core Insights - The company is strategically expanding into the small RNA platform to address age-related chronic diseases, aiming to develop a pipeline with long-term value and transition into a Pharma company [1][2]. Group 1: Company Overview - The company has established a partnership with AditumBio to form KalexoBio, focusing on a dual-target siRNA drug, 2MW7141, for cardiovascular diseases, with a total deal value of $1 billion [2]. - The company has a strong asset management background, with the fund managing assets of 16.182 billion yuan and achieving a one-year return of 54.74% for its best-performing fund [1]. Group 2: Product Development - The dual-target siRNA drug 2MW7141 is designed to address unmet clinical needs in cardiovascular treatment, with preliminary data showing strong efficacy in animal models [3][5]. - The siRNA technology platform emphasizes differentiated innovation, utilizing AI for automated design and screening, and optimizing delivery methods for both liver-targeted and extrahepatic applications [4]. Group 3: Research and Clinical Trials - The α-synuclein-targeting PET tracer [18F]-FD4 has received funding from the Michael J. Fox Foundation to accelerate its development for Parkinson's disease and related disorders, with potential for early diagnosis and monitoring [6][7]. - The company is advancing multiple clinical pipelines, including 9MW2821 for bladder cancer and 9MW1911 for COPD, with significant milestones expected in the coming years [8][9].